Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib
Calliditas Therapeutics AB - American Depositary Shares (CALT)
Company Research
Source: PR Newswire
STOCKHOLM, May 6, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced data from the proof-of-concept Phase 2 trial evaluating setanaxib, its lead NOX enzyme inhibitor, in combination with pembrolizumab, in patients with squamous cell carcinoma of the head and neck (SCCHN). The analysis showed statistically significant improvements in progression-free survival (PFS), as well as in overall survival (OS), with statistically significant changes in tumor biology consistent with the mechanism of action of setanaxib. The trial is a randomized, placebo-controlled, double-blind Phase 2 study investigating the effect of setanaxib 800mg twice daily in conjunction with pembrolizumab 200mg IV, administered every 3 weeks (a standard treatment regimen for SCCHN) with the full dataset reflecting all patients having had the opportunity to complete at least 15 weeks of treatment. The basis for the analysis consisted of a dataset of 55
Show less
Read more
Impact Snapshot
Event Time:
CALT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CALT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CALT alerts
High impacting Calliditas Therapeutics AB - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
CALT
News
- Three Growth Companies With High Insider Ownership And At Least 15% Revenue Growth [Yahoo! Finance]Yahoo! Finance
- Exploring Three Growth Companies With High Insider Stakes [Yahoo! Finance]Yahoo! Finance
- Swedish Growth Companies With At Least 21% Insider Ownership On The Rise [Yahoo! Finance]Yahoo! Finance
- Swedish Exchange Highlights: 3 Growth Companies With Insider Ownership Reaching 35% [Yahoo! Finance]Yahoo! Finance
- In-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO's Mode of ActionPR Newswire
CALT
Analyst Actions
- 2/22/24 - HC Wainwright
CALT
Sec Filings
- 5/16/24 - Form 6-K
- 5/6/24 - Form 6-K
- 4/25/24 - Form 6-K
- CALT's page on the SEC website